Latest news

InsightsJuly 31, 2026

Top 10 Strategic Priorities for Pharmaceutical Leaders in 2026

Executive Summary The pharmaceutical industry is entering a period of profound transformation. While scientific innovation remains the foundation of long-term...

InsightsJuly 31, 2026

Why Data Quality Is Becoming Pharma’s Biggest AI Challenge

Executive Summary Artificial intelligence (AI) has become one of the pharmaceutical industry's most important strategic priorities. Companies are investing heavily in...

CommercialJuly 31, 2026

Lilly challenges J&J in the market for psychedelic mental health by paying $2.8 billion up front for AtaiBeckley

Eli Lilly has inked the deal to purchase AtaiBeckley for $2.8 billion to continue its acquisition spree in a...

InsightsJuly 31, 2026

The Next Wave of Innovation in Oncology

Executive Summary Oncology remains one of the most dynamic and rapidly evolving areas of pharmaceutical innovation. Over the past two decades,...

ClinicalJuly 30, 2026

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Hansoh Pharmaceutical has recorded another late-stage success for its...

ClinicalJuly 28, 2026

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

Altimmune has reported topline results from its Phase 2...

CommercialJuly 28, 2026

Included Health Agrees to Acquire Firefly Health to Expand Employer Health Plan Alternatives

Virtual care and health navigation company Included Health has agreed to acquire Firefly Health as it seeks to scale...

InsightsJuly 28, 2026

The Workforce Challenge Facing Biopharma Manufacturing

Executive Summary Biopharmaceutical manufacturing is entering one of the most important periods of transformation in its history. Demand for advanced therapies,...

CommercialJuly 27, 2026

Argenx purchases Forte for $2.2 billion to enter the hands-on phase two-stage medication for vitiligo

Forte Biosciences is being acquired by Argenx for $2.2 billion in a deal that has two stages: phase 2...

InsightsJuly 27, 2026

What Pharma Leaders Are Prioritizing in 2026

Executive Summary The pharmaceutical industry is entering a new phase...

RegulatoryJuly 26, 2026

Takeda’s Qdenga Makes History as First Vaccine to Get the Nod in India

Takeda has secured approval from the Drug Controller General...

CommercialJuly 26, 2026

Tempus purchases a specialist in cancer genomics in a $1.5 billion deal: Personalis

Since the two first joined forces in oncology three years ago, Tempus is expanding its cancer programs with plans...

InsightsJuly 26, 2026

How RNA Therapeutics Are Expanding Beyond Rare Diseases

Executive Summary RNA therapeutics have emerged as one of the most significant innovations in modern medicine. Initially developed to address rare...

CommercialJuly 26, 2026

Samsung Biologics Plans $1.8 Billion Acquisition of PolyPeptide

Samsung Biologics has announced plans to acquire Swiss contract development and manufacturing organization (CDMO) PolyPeptide in a transaction valued...